Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC

Fig. 4

PLC-β2-related features in sub-populations enriched in CD133+ and/or EpCAM+ cells. In a representative fluorescence microscopy images of MDA-MB-231 sub-populations enriched in CD133/EpCAM, CD133/EpCAM+, CD133+/EpCAM and CD133+/EpCAM+ cells subjected to immunocytochemical analysis with the anti-PLC-β2 antibody. The fluorescence intensity of PLC-β2 staining was calculated in digitized images by the ImageJ software and reported in b as arbitrary units. In c immunocytochemical analysis of the indicated sub-populations after simultaneous staining with the anti-PLC-β2 antibody (green fluorescence) and with the anti-CD133 or anti- EpCAM antibody (red fluorescence). In d the enriched CD133+/EpCAM+ sub-population was transfected with siRNAs specific for PLC-β2 (PLC-β2 siRNAs) or with a construct expressing the human PLC-β2 (Over PLC-β2) and subjected to simultaneous flow cytometry analysis of CD133 and EpCAM surface expression. Non-silencing scramble siRNAs or an empty vector were used as controls (Ctrl). In each experimental condition, fold change is compared with Ctrl, taken as 1. Proliferation and invasiveness of cells in the same experimental conditions were measured by the xCELLigence system (e). All the data are the mean of three separate experiments performed in triplicate ± SD. *P < 0.05. Bar = 20 μm

Back to article page
\